CDH1
CDH1 (Cadherin-1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Breast cancer, Ovarian cancer and 5 more.
Overview
Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. CDH1 is involved in mechanisms regulating cell-cell adhesions, mobility and proliferation of epithelial cells.
CIViC holds 8 clinical evidence items and 0 assertions across 6 variants, naming Crizotinib, Pazopanib, Foretinib and Palbociclib Regimen. Open Targets scores its association with cancer at 0.90 (direct and indirect evidence; datatypes genetic literature 0.82, affected pathway 0.54, literature 1.00, genetic association 0.83, somatic mutation 0.96). IntOGen calls it a driver in 18 cohorts (3 activating, 14 loss-of-function), covering Bladder Urothelial Carcinoma, Invasive Breast Carcinoma, Cutaneous Squamous Cell Carcinoma, Diffuse Large B-Cell Lymphoma, NOS, Oesophageal Adenocarcinoma, Stomach Adenocarcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · CDH1 (Cadherin-1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Breast cancer, Ovarian cancer and 5 more.
- 1 · What it is
CDH1 (Cadherin-1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Breast cancer, Ovarian cancer and 5 more.
- 2 · What goes wrong in cancer
Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types.
- 3 · How drugs use it
No product in this corpus aims at CDH1 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:1748 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P12830 (protein name, function text, keywords and locations (REST API)); CIViC gene CDH1 (8 evidence items, 0 assertions, 6 variants; diseases: Breast Cancer, Cholangiocarcinoma, Stomach Carcinoma (GraphQL API, CC0)); Open Targets ENSG00000039068 (association with cancer (MONDO_0004992) 0.90; per-cancer scores at or above 0.5: colorectal cancer 0.55, gastric cancer 0.84, prostate cancer 0.67, ovarian cancer 0.72, endometrial cancer 0.71, skin cancer 0.58 (GraphQL API, CC0)); IntOGen CDH1 (driver in 18 cohorts (Act 3, LoF 14); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. CDH1 is involved in mechanisms regulating cell-cell adhesions, mobility and proliferation of epithelial cells. Promotes organisation of radial actin fibre structure and cellular response to contractile forces, via its interaction with AMOTL2 which facilitates anchoring of radial actin fibres to CDH1 junction complexes at the cell membrane. Plays a role in the early stages of desmosome cell-cell junction formation via facilitating the recruitment of DSG2 and DSP to desmosome plaques. Has a potent invasive suppressor role. Location: Cell junction, adherens junction; Cell membrane; Endosome; Golgi apparatus, trans-Golgi network (UniProt). Locus 16q22.1 (HGNC).
- Gastric & gastro-oesophageal junction cancer: Open Targets association 0.84 with gastric cancer (MONDO_0001056); CIViC evidence names this disease
- Breast cancer: Open Targets association 0.82 with breast cancer (MONDO_0007254); CIViC evidence names this disease
- Ovarian cancer: Open Targets association 0.72 with ovarian cancer (MONDO_0008170)
- Endometrial cancer: Open Targets association 0.71 with endometrial cancer (MONDO_0011962)
- Prostate cancer: Open Targets association 0.67 with prostate cancer (MONDO_0008315)
- Bladder & urothelial cancer: IntOGen driver in 2 cohorts (BLCA)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 4 therapies; IntOGen calls it an activating (Act) driver in 3 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 14 cohorts; CIViC holds 8 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"CDH1" OR ABSTRACT:"CDH1" OR TITLE:"cadherin 1" OR ABSTRACT:"cadherin 1" OR TITLE:"Cadherin-1" OR ABSTRACT:"Cadherin-1" OR TITLE:"uvomorulin" OR ABSTRACT:"uvomorulin" OR TITLE:"CD324" OR ABSTRACT:"CD324") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CDH1, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetAPC
Shares Gastric cancer (KEGG map), Oesophageal cancer, CIViC, IntOGen.
- TreatmentBemarituzumab
Shares Gastric cancer (KEGG map), Gastric & gastro-oesophageal junction cancer.
- PathwayFGF / FGFR signalling
Shares Gastric cancer (KEGG map), Bladder & urothelial cancer, Gastric & gastro-oesophageal junction cancer.
- TreatmentZolbetuximab
Shares Gastric cancer (KEGG map), Oesophageal cancer, Gastric & gastro-oesophageal junction cancer.
- TreatmentZanidatamab
Shares Gastric cancer (KEGG map), Oesophageal cancer, Gastric & gastro-oesophageal junction cancer.
- PathwayMismatch repair & microsatellite instability
Shares Gastric cancer (KEGG map), Endometrial cancer, Gastric & gastro-oesophageal junction cancer.
- TreatmentRamucirumab
Shares Gastric cancer (KEGG map), Oesophageal cancer, Gastric & gastro-oesophageal junction cancer.